Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

Key Points

• Rein Therapeutics reported quarterly EPS of $(0.10), beating the consensus estimate of $(0.27) by $0.17.
• The stock rose 2.3% to about $0.81, but remains well below its 12-month high of $2.18; institutional investors own approximately 90.89% of shares.
• Analyst sentiment is mixed, with an average rating of “Hold” and a $6.00 average price target. The company is developing its RT-101 tumor-activated IL-12 therapy in early-stage trials for solid tumors.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17, Zacks reports.

Rein Therapeutics Stock Up 2.3%

Rein Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $0.81. The company's stock had a trading volume of 211,019 shares, compared to its average volume of 424,245. Rein Therapeutics has a 12 month low of $0.69 and a 12 month high of $2.18. The business's 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.14.

Institutional Investors Weigh In On Rein Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in RNTX. Susquehanna International Group LLP bought a new position in shares of Rein Therapeutics in the 3rd quarter valued at about $35,000. HRT Financial LP bought a new stake in Rein Therapeutics during the fourth quarter worth about $38,000. Northwestern Mutual Wealth Management Co. bought a new stake in Rein Therapeutics during the second quarter worth about $68,000. Jane Street Group LLC acquired a new position in Rein Therapeutics during the fourth quarter valued at approximately $72,000. Finally, State Street Corp boosted its position in Rein Therapeutics by 374.3% during the fourth quarter. State Street Corp now owns 75,904 shares of the company's stock valued at $88,000 after purchasing an additional 59,900 shares during the last quarter. 90.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. HC Wainwright reduced their target price on shares of Rein Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, June 1st. Maxim Group initiated coverage on Rein Therapeutics in a research note on Monday, July 20th. They issued a "buy" rating and a $4.00 price target on the stock. Weiss Ratings upgraded Rein Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded Rein Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Rein Therapeutics presently has an average rating of "Hold" and an average target price of $6.00.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source